ArticleJournal of gastrointestinal oncology2026
The impact of ulinastatin on postoperative clinical outcomes in patients with gastric cancer: a retrospective cohort analysis.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Excessive perioperative inflammation in gastric cancer (GC) surgery contributes to delayed recovery, complications, and impaired immune function. Ulinastatin (UTI) has shown anti-inflammatory effects in other surgical settings, but its role in laparoscopic gastrectomy for GC remains unclear. This study evaluated the effect of intraoperative UTI on postoperative inflammation and early recovery. Methods: This retrospective cohort study included 415 adults undergoing elective laparoscopic gastrectomy for primary gastric adenocarcinoma between January 2021 and January 2023. Patients receiving 300,000 units of UTI intravenously intraoperatively (UTI group, n=53) were compared with those who did not (Control group, n=362). Propensity score matching (PSM) (1:1) balanced baseline characteristics. Postoperative inflammatory markers [C-reactive protein (CRP), white blood cell count (WBC), neutrophil count (NEUT)], and liver function indices [aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (Tbil)] were assessed at postoperative day 1 and 3. Linear mixed-effects models analyzed longitudinal changes, and multivariable regression identified predictors of hospital stay. Results: After matching, 50 patients per group were analyzed. At postoperative day 3, CRP elevation was lower in the UTI group versus Control [mean difference -22.88±24.64 mg/L (mean ± standard deviation); P=0.04]. ALT increase was also reduced (mean difference -20.22±15.20 U/L; P=0.01). However, WBC, NEUT, AST, Tbil, and hospital stay showed no significant differences. Diabetes history was independently associated with prolonged hospitalization [β=3.35; 95% confidence interval (CI): 1.67-4.98; P=0.03]. Conclusions: Intraoperative UTI attenuates postoperative CRP and ALT elevation, reflecting anti-inflammatory and partial hepatoprotective effects. Integration of UTI into comprehensive perioperative management may enhance clinical recovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.